Home ›
Lung Cancer Trials ›
NCT07139990
Personalized Radiotherapy for Individualized Treatment Strategies and Monitoring (PRISM)
To characterize feasibility, safety, and/or preliminary efficacy of personalized strategies to adapt standard radiotherapy treatments to individual patient responses.
Trial Details
NCT ID NCT07139990
Phase PHASE1
Sponsor University of Texas Southwestern Medical Center
Status RECRUITING
Cancer Type Lung Cancer
Interventions Cohort A: Extensive Stage Small Cell Lung Cancer (ES-SCLC) Thoracic Tumor PULSAR (Personalized ultrahypofractionated stereotactic ablative radiotherapy) Cohort B: Brain metastasis PULSAR (Personalized ultrahypofractionated stereotactic ablative radiotherapy) Cohort C: Sarcoma Pre-Operative PULSAR Cohort D: Resectable Head & Neck Squamous Cell Carcinoma (HNSCC) PULSAR/SAbR
Locations (sample) Dallas, Texas, United States|32.78306,-96.80667
Key Eligibility Criteria
\>=18 years old Performance status ECOG 0-2 Extensive stage small cell lung cancer diagnosed by tissue biopsy within 180 days of registration. Patient must be planned for or receiving standard of care chemoimmunotherapy.
For full eligibility, visit ClinicalTrials.gov .
Check If You May Be Eligible
Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.
Find Lung Cancer Trials on Trialify →